Related Experiment Videos
Isoprenoids and Ras: potential role in chronic rejection
M P O'Donnell1, B L Kasiske, Z A Massy
1Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA.
Kidney International. Supplement
|December 1, 1995
Summary
Inhibiting Ras protein prenylation or activation may reduce chronic allograft rejection. Studies show lovastatin and leflunomide treatments significantly decrease allograft intimal area in rat models.
Area of Science:
- Immunology
- Molecular Biology
- Cellular Biology
Background:
- Protein prenylation is a post-translational modification crucial for protein localization and function.
- The protooncogene product Ras is a key signaling molecule involved in cell proliferation and differentiation.
- Ras activation by growth factors and cytokines plays a role in various cellular events.
Purpose of the Study:
- To investigate the role of Ras in chronic allograft rejection.
- To evaluate the therapeutic potential of inhibiting Ras prenylation or activation in allograft rejection.
Main Methods:
- Utilized a rat model of abdominal aorta transplantation (Lewis to Buffalo rats).
- Administered HMG-CoA reductase inhibitor (lovastatin) to inhibit isoprenoid production and block Ras prenylation.
- Administered leflunomide to inhibit growth factor receptor tyrosine kinases and block Ras activation.
Main Results:
- Lovastatin treatment significantly reduced allograft intimal area compared to controls.
- Leflunomide treatment also significantly reduced allograft intimal area.
- These findings suggest Ras is involved in chronic allograft rejection.
Conclusions:
- Ras signaling appears to be important in the pathogenesis of chronic allograft rejection.
- Interfering with Ras protein prenylation or its activation by growth factor receptors may offer a therapeutic strategy to ameliorate chronic rejection.